AR067897A1 - Compuestos para el tratamiento de hepatitis c - Google Patents
Compuestos para el tratamiento de hepatitis cInfo
- Publication number
- AR067897A1 AR067897A1 ARP080103488A ARP080103488A AR067897A1 AR 067897 A1 AR067897 A1 AR 067897A1 AR P080103488 A ARP080103488 A AR P080103488A AR P080103488 A ARP080103488 A AR P080103488A AR 067897 A1 AR067897 A1 AR 067897A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- dialkylamino
- alkylamino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 27
- 239000001257 hydrogen Substances 0.000 abstract 12
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 12
- -1 hydroxy, benzyloxy Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 5
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 5
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 4
- 125000004193 piperazinyl group Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000002393 azetidinyl group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000002757 morpholinyl group Chemical group 0.000 abstract 3
- 125000003386 piperidinyl group Chemical group 0.000 abstract 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 229910003844 NSO2 Inorganic materials 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95481407P | 2007-08-09 | 2007-08-09 | |
| US4994408P | 2008-05-02 | 2008-05-02 | |
| US12/180,994 US7652004B2 (en) | 2007-08-09 | 2008-07-28 | Compounds for the treatment of hepatitis C |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067897A1 true AR067897A1 (es) | 2009-10-28 |
Family
ID=40261456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103488A AR067897A1 (es) | 2007-08-09 | 2008-08-08 | Compuestos para el tratamiento de hepatitis c |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7652004B2 (https=) |
| EP (1) | EP2183252B1 (https=) |
| JP (1) | JP5465670B2 (https=) |
| KR (1) | KR20100066492A (https=) |
| CN (1) | CN101821267B (https=) |
| AR (1) | AR067897A1 (https=) |
| AU (1) | AU2008293845B2 (https=) |
| BR (1) | BRPI0814931A2 (https=) |
| CA (1) | CA2695781A1 (https=) |
| CL (1) | CL2008002353A1 (https=) |
| CO (1) | CO6251359A2 (https=) |
| EA (1) | EA015978B1 (https=) |
| MX (1) | MX2010001416A (https=) |
| NZ (1) | NZ583149A (https=) |
| PE (1) | PE20090618A1 (https=) |
| TW (1) | TW200906418A (https=) |
| WO (1) | WO2009029384A2 (https=) |
| ZA (1) | ZA201000923B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途 |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| KR20100108341A (ko) * | 2007-11-20 | 2010-10-06 | 브리스톨-마이어스 스큅 컴퍼니 | 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| KR20100124848A (ko) | 2008-03-27 | 2010-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| JP2012517468A (ja) * | 2009-02-11 | 2012-08-02 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎治療のための化合物 |
| CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| CH706864B1 (de) | 2011-06-22 | 2016-03-31 | Central Glass Co Ltd | Verfahren zur Herstellung einer Pyrazol-Verbindung. |
| JP5915004B2 (ja) * | 2011-06-22 | 2016-05-11 | セントラル硝子株式会社 | ピラゾール化合物の製造方法 |
| EP3091022A3 (en) * | 2012-07-18 | 2016-12-14 | Bristol-Myers Squibb Holdings Ireland | Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20090250T1 (hr) | 2004-02-24 | 2009-06-30 | Japan Tobacco | Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EP1807403A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) * | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| JP5205370B2 (ja) * | 2006-05-25 | 2013-06-05 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| WO2007140200A2 (en) * | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| US7452876B2 (en) * | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) * | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) * | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2008
- 2008-07-28 US US12/180,994 patent/US7652004B2/en active Active
- 2008-08-01 MX MX2010001416A patent/MX2010001416A/es active IP Right Grant
- 2008-08-01 EP EP08828571.3A patent/EP2183252B1/en not_active Not-in-force
- 2008-08-01 JP JP2010520215A patent/JP5465670B2/ja not_active Expired - Fee Related
- 2008-08-01 BR BRPI0814931-3A2A patent/BRPI0814931A2/pt not_active IP Right Cessation
- 2008-08-01 CN CN2008801108622A patent/CN101821267B/zh not_active Expired - Fee Related
- 2008-08-01 CA CA2695781A patent/CA2695781A1/en not_active Abandoned
- 2008-08-01 AU AU2008293845A patent/AU2008293845B2/en not_active Ceased
- 2008-08-01 EA EA201000277A patent/EA015978B1/ru not_active IP Right Cessation
- 2008-08-01 KR KR1020107005086A patent/KR20100066492A/ko not_active Withdrawn
- 2008-08-01 NZ NZ583149A patent/NZ583149A/en not_active IP Right Cessation
- 2008-08-01 WO PCT/US2008/071881 patent/WO2009029384A2/en not_active Ceased
- 2008-08-08 TW TW097130410A patent/TW200906418A/zh unknown
- 2008-08-08 PE PE2008001327A patent/PE20090618A1/es not_active Application Discontinuation
- 2008-08-08 CL CL200802353A patent/CL2008002353A1/es unknown
- 2008-08-08 AR ARP080103488A patent/AR067897A1/es unknown
-
2010
- 2010-02-03 CO CO10011252A patent/CO6251359A2/es not_active Application Discontinuation
- 2010-02-08 ZA ZA2010/00923A patent/ZA201000923B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7652004B2 (en) | 2010-01-26 |
| AU2008293845B2 (en) | 2013-02-14 |
| AU2008293845A1 (en) | 2009-03-05 |
| MX2010001416A (es) | 2010-03-01 |
| EA015978B1 (ru) | 2012-01-30 |
| CO6251359A2 (es) | 2011-02-21 |
| US20090074715A1 (en) | 2009-03-19 |
| WO2009029384A2 (en) | 2009-03-05 |
| JP2010535787A (ja) | 2010-11-25 |
| ZA201000923B (en) | 2011-04-28 |
| EP2183252A2 (en) | 2010-05-12 |
| EA201000277A1 (ru) | 2010-06-30 |
| PE20090618A1 (es) | 2009-05-16 |
| KR20100066492A (ko) | 2010-06-17 |
| WO2009029384A3 (en) | 2009-05-28 |
| CN101821267B (zh) | 2013-07-10 |
| EP2183252B1 (en) | 2015-01-14 |
| JP5465670B2 (ja) | 2014-04-09 |
| CL2008002353A1 (es) | 2008-10-24 |
| NZ583149A (en) | 2011-07-29 |
| CA2695781A1 (en) | 2009-03-05 |
| TW200906418A (en) | 2009-02-16 |
| CN101821267A (zh) | 2010-09-01 |
| BRPI0814931A2 (pt) | 2015-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067897A1 (es) | Compuestos para el tratamiento de hepatitis c | |
| CO6180426A2 (es) | Compuesto para el tratamiento de la hepatitis b | |
| AR055165A1 (es) | Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. | |
| AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
| AR073740A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| NZ515664A (en) | Benzimidazole derivatives useful as respiratory syncytial virus replication inhibitors | |
| AR071684A1 (es) | Compuestos para el tratamiento de la hepatitis c | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| AR067542A1 (es) | Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| ECSP045317A (es) | Piridinoilpiperidinas como agonistas de 5-ht1f | |
| AR062928A1 (es) | Inhibidores de la actividad quinasa utiles en el tratamiento de trastornos mediados por mecanismos de ikk2 | |
| MX2009005449A (es) | Compuesto heteromonociclico y uso del mismo. | |
| PE20090151A1 (es) | Derivados de pirimidinona y metodos para su uso | |
| AR067528A1 (es) | Eteres heterociclicos sustituidos y su uso en trastornos del snc | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR053406A1 (es) | Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| MX2012006962A (es) | Inhibidores de la esfingosina quinasa. | |
| TW200716531A (en) | Cyclohexanesulfonyl derivatives as GLYT1 inhibitors to treat schizophrenia | |
| MX2009010660A (es) | Derivados de purina substituidos-2,6,9 que tienen propiedades anti-proliferativas. | |
| AR056319A1 (es) | Inhibidores de orto-terfinilo de p38 quinasa, composicion farmaceutica y compuestos intermedios | |
| PT2280706E (pt) | Composições compreendendo derivados de benzeno que activam lipase de lipoproteína |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |